Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties to Improve Prostate Cancer Therapy.

Umbricht CA, Benesova M, Schibli R, Müller C.

Mol Pharm. 2018 Apr 23. doi: 10.1021/acs.molpharmaceut.8b00152. [Epub ahead of print]

PMID:
29684274
2.

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.

Müeller C, Domnanich KA, Umbricht CA, van der Meulen NP.

Br J Radiol. 2018 Apr 16:20180074. doi: 10.1259/bjr.20180074. [Epub ahead of print]

PMID:
29658792
3.

Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.

Kranzbühler B, Salemi S, Umbricht CA, Müller C, Burger IA, Sulser T, Eberli D.

Prostate. 2018 Apr 6. doi: 10.1002/pros.23522. [Epub ahead of print]

PMID:
29633296
4.

Validation of a personalized risk prediction model for contralateral breast cancer.

Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P.

Breast Cancer Res Treat. 2018 Mar 24. doi: 10.1007/s10549-018-4763-5. [Epub ahead of print]

PMID:
29574637
5.

Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.

Benešová M, Umbricht CA, Schibli R, Müller C.

Mol Pharm. 2018 Mar 5;15(3):934-946. doi: 10.1021/acs.molpharmaceut.7b00877. Epub 2018 Feb 5.

PMID:
29400475
6.

Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset?

Sahli ZT, Umbricht CB, Schneider EB, Zeiger MA.

Thyroid. 2017 Nov;27(11):1393-1399. doi: 10.1089/thy.2017.0238. Epub 2017 Sep 28.

PMID:
28859553
7.

Positive Ultrasound-guided Lymph Node Needle Biopsy in Breast Cancer may not Mandate Axillary Lymph Node Dissection.

Harris CK, Tran HT, Lee K, Mylander C, Pack D, Rosman M, Tafra L, Umbricht CB, Andrade R, Liang W, Jackson RS.

Ann Surg Oncol. 2017 Oct;24(10):3004-3010. doi: 10.1245/s10434-017-5935-y. Epub 2017 Aug 1.

PMID:
28766210
8.

Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.

Lai X, Umbricht CB, Fisher K, Bishop J, Shi Q, Chen S.

J Proteomics. 2017 Aug 23;166:59-67. doi: 10.1016/j.jprot.2017.07.003. Epub 2017 Jul 12.

PMID:
28709933
9.

β-Integrin de-phosphorylation by the Density-Enhanced Phosphatase DEP-1 attenuates EGFR signaling in C. elegans.

Walser M, Umbricht CA, Fröhli E, Nanni P, Hajnal A.

PLoS Genet. 2017 Jan 30;13(1):e1006592. doi: 10.1371/journal.pgen.1006592. eCollection 2017 Jan.

10.

44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.

Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, Müller C.

EJNMMI Res. 2017 Dec;7(1):9. doi: 10.1186/s13550-017-0257-4. Epub 2017 Jan 19.

11.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L.

J Clin Oncol. 2016 Dec 20;34(36):4390-4397. Epub 2016 Oct 31.

12.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

13.

Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review).

Avin BA, Umbricht CB, Zeiger MA.

Int J Oncol. 2016 Dec;49(6):2199-2205. doi: 10.3892/ijo.2016.3743. Epub 2016 Oct 20. Review.

PMID:
27779655
14.

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ 3rd, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.

Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7.

15.

MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review.

Aragon Han P, Weng CH, Khawaja HT, Nagarajan N, Schneider EB, Umbricht CB, Witwer KW, Zeiger MA.

Thyroid. 2015 Dec;25(12):1322-9. doi: 10.1089/thy.2015.0193. Epub 2015 Oct 8. Review.

PMID:
26414548
16.

A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.

Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC, Tafra L.

Clin Breast Cancer. 2015 Dec;15(6):467-72. doi: 10.1016/j.clbc.2015.04.006. Epub 2015 Apr 23.

17.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

18.

Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors.

Timp W, Bravo HC, McDonald OG, Goggins M, Umbricht C, Zeiger M, Feinberg AP, Irizarry RA.

Genome Med. 2014 Aug 26;6(8):61. doi: 10.1186/s13073-014-0061-y. eCollection 2014.

19.

Do breast cancer cell lines provide a relevant model of the patient tumor methylome?

Cope LM, Fackler MJ, Lopez-Bujanda Z, Wolff AC, Visvanathan K, Gray JW, Sukumar S, Umbricht CB.

PLoS One. 2014 Aug 26;9(8):e105545. doi: 10.1371/journal.pone.0105545. eCollection 2014.

20.

Lower vitamin D levels in surgical hyperparathyroidism versus thyroid patients.

Lindeman BM, Pesce CE, Tsai HL, Somervell H, Umbricht CB, Kowalski J, Zeiger MA.

Am Surg. 2014 May;80(5):505-10.

21.

Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S.

Cancer Res. 2014 Apr 15;74(8):2160-70. doi: 10.1158/0008-5472.CAN-13-3392. Erratum in: Cancer Res. 2014 Jun 1;74(11):3196.

22.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

23.

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.

Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA.

J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. doi: 10.1210/jc.2013-1584. Epub 2013 Aug 22.

PMID:
23969188
24.

HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C, Sukumar S.

Cancer Res. 2013 Sep 1;73(17):5449-58. doi: 10.1158/0008-5472.CAN-13-1178. Epub 2013 Jul 5.

25.

A tertiary center's experience with second review of 3885 thyroid cytopathology specimens.

Olson MT, Boonyaarunnate T, Aragon Han P, Umbricht CB, Ali SZ, Zeiger MA.

J Clin Endocrinol Metab. 2013 Apr;98(4):1450-7. doi: 10.1210/jc.2012-3898. Epub 2013 Feb 22.

PMID:
23436916
26.

DNA copy number variations characterize benign and malignant thyroid tumors.

Liu Y, Cope L, Sun W, Wang Y, Prasad N, Sangenario L, Talbot K, Somervell H, Westra W, Bishop J, Califano J, Zeiger M, Umbricht C.

J Clin Endocrinol Metab. 2013 Mar;98(3):E558-66. doi: 10.1210/jc.2012-3113. Epub 2013 Jan 23.

27.

Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA.

Surgery. 2012 Dec;152(6):977-83. doi: 10.1016/j.surg.2012.08.019. Epub 2012 Oct 11.

28.

Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.

Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO.

Epigenetics. 2012 Jul;7(7):710-9. doi: 10.4161/epi.20524. Epub 2012 Jul 1.

29.

Three-gene molecular diagnostic model for thyroid cancer.

Prasad NB, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw AP, Westra WH, Clark DP, Libutti SK, Umbricht CB, Zeiger MA.

Thyroid. 2012 Mar;22(3):275-84. doi: 10.1089/thy.2011.0169. Epub 2012 Jan 26.

30.

Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.

Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, Sukumar S.

Cancer Res. 2011 Oct 1;71(19):6195-207. doi: 10.1158/0008-5472.CAN-11-1630. Epub 2011 Aug 8.

31.

Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Wang Y, Meeker AK, Kowalski J, Tsai HL, Somervell H, Heaphy C, Sangenario LE, Prasad N, Westra WH, Zeiger MA, Umbricht CB.

Am J Pathol. 2011 Sep;179(3):1415-24. doi: 10.1016/j.ajpath.2011.05.056. Epub 2011 Jul 16.

32.

Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer.

Gomez NR, Kouniavsky G, Tsai HL, Somervell H, Pai SI, Tufano RP, Umbricht C, Kowalski J, Dackiw AP, Zeiger MA.

J Surg Oncol. 2011 Nov 1;104(6):613-6. doi: 10.1002/jso.21891. Epub 2011 Jul 8.

PMID:
21744345
33.

Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.

Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang Y, Kong B, Langerød A, Børresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY.

Nat Genet. 2011 Jun 5;43(7):621-9. doi: 10.1038/ng.848.

34.

Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer.

Marik R, Allu M, Anchoori R, Stearns V, Umbricht CB, Khan S.

Cancer Biol Ther. 2011 May 15;11(10):883-92. Epub 2011 May 15.

35.

Postoperative hypocalcemia after thyroidectomy for Graves' disease.

Pesce CE, Shiue Z, Tsai HL, Umbricht CB, Tufano RP, Dackiw AP, Kowalski J, Zeiger MA.

Thyroid. 2010 Nov;20(11):1279-83. doi: 10.1089/thy.2010.0047. Epub 2010 Oct 18.

PMID:
20950255
36.

Chasing "shadows": discovering the subtleties of sestamibi scans to facilitate minimally invasive parathyroidectomy.

Neychev VK, Kouniavsky G, Shiue Z, Udall DN, Somervell H, Umbricht CB, Zeiger MA.

World J Surg. 2011 Jan;35(1):140-6. doi: 10.1007/s00268-010-0800-1.

PMID:
20886211
37.

DNA methylation-related vitamin D receptor insensitivity in breast cancer.

Marik R, Fackler M, Gabrielson E, Zeiger MA, Sukumar S, Stearns V, Umbricht CB.

Cancer Biol Ther. 2010 Jul 1;10(1):44-53. Epub 2010 Jul 9.

38.

Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy.

Morita SY, Somervell H, Umbricht CB, Dackiw AP, Zeiger MA.

Surgery. 2008 Dec;144(6):862-6; discussion 866-8. doi: 10.1016/j.surg.2008.07.029.

PMID:
19040989
39.

Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Wang Y, Kowalski J, Tsai HL, Marik R, Prasad N, Somervell H, Lo PK, Sangenario LE, Dyrskjot L, Orntoft TF, Westra WH, Meeker AK, Eshleman JR, Umbricht CB, Zeiger MA.

Thyroid. 2008 Oct;18(10):1055-63. doi: 10.1089/thy.2008.0101.

40.

A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples.

Banks ND, Kowalski J, Tsai HL, Somervell H, Tufano R, Dackiw AP, Marohn MR, Clark DP, Umbricht CB, Zeiger MA.

Thyroid. 2008 Sep;18(9):933-41. doi: 10.1089/thy.2008.0108.

PMID:
18788917
41.

Identification of genes differentially expressed in benign versus malignant thyroid tumors.

Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA.

Clin Cancer Res. 2008 Jun 1;14(11):3327-37. doi: 10.1158/1078-0432.CCR-07-4495.

42.

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.

Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M.

Int J Cancer. 2006 Nov 15;119(10):2322-9.

43.

A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.

Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK.

Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7.

PMID:
16360390
44.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW.

J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9. Epub 2005 Sep 20.

PMID:
16174717
45.

Modern approaches to age-old questions about thyroid tumors.

Diehl S, Umbricht CB, Dackiw AP, Zeiger MA.

Thyroid. 2005 Jun;15(6):575-82. Review.

PMID:
16029124
46.

Quantitative assessment of promoter methylation profiles in thyroid neoplasms.

Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB.

J Clin Endocrinol Metab. 2005 Jul;90(7):4011-8. Epub 2005 Apr 19. Erratum in: J Clin Endocrinol Metab. 2006 Sep;91(9):3278.

PMID:
15840741
47.

Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors.

Umbricht CB, Conrad GT, Clark DP, Westra WH, Smith DC, Zahurak M, Saji M, Smallridge RC, Goodman S, Zeiger MA.

Clin Cancer Res. 2004 Sep 1;10(17):5762-8.

48.

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.

Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH.

Clin Cancer Res. 2004 Apr 15;10(8):2761-5.

49.

Using gene expression profiling to differentiate benign versus malignant thyroid tumors.

Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK.

Cancer Res. 2004 Apr 15;64(8):2898-903. Erratum in: Cancer Res. 2004 Jul 15;64(14):5028. Costourous N [corrected to Costouros NG].

50.

Beyond the suspicious thyroid fine needle aspirate. A review.

Segev DL, Clark DP, Zeiger MA, Umbricht C.

Acta Cytol. 2003 Sep-Oct;47(5):709-22. Review.

PMID:
14526667

Supplemental Content

Loading ...
Support Center